Effective vaccine development for global outbreaks, such as the coronavirus disease 2019 (COVID-19), has been successful in the short run. However, the currently available vaccines have been associated with a higher frequency of adverse effects compared with other general vaccines. In this study, the possibility of an oral bacteria-based vaccine that can be safely used as a platform for large-scale, long-term immunization was evaluated. A well-known Salmonella strain that was previously considered as a vaccine delivery candidate was used. Recombinant Salmonella cells expressing engineered viral proteins related with COVID-19 pathogenesis were engineered, and the formulation of the oral vaccine candidate strain was evaluated by in vitro and in vivo experiments. First, engineered S proteins were synthesized and cloned into expression vectors, which were than transformed into Salmonella cells. In addition, when orally administrated to mice, the vaccine promoted antigen-specific antibody production and cellular immunity was induced with no significant toxicity effects. These results suggest that Salmonella strains may represent a valuable platform for the development of an oral vaccine for COVID-19 as an alternative to tackle the outbreak of various mutated coronavirus strains and new infectious diseases in the future.
【저자키워드】 SARS-CoV-2, Spike protein, Oral vaccine, Salmonella, 【초록키워드】 COVID-19, coronavirus disease, Vaccine, Vaccine development, Pathogenesis, Vaccines, S protein, Toxicity, Infectious disease, in vitro, immunization, Outbreaks, cellular immunity, cells, outbreak, mice, platform, Salmonella, Frequency, recombinant, strain, adverse effect, Viral protein, antigen-specific antibody, expression vectors, Effects, Cell, was used, cloned, addition, evaluated, coronavirus strain, mutated, expressing, the vaccine, promoted, in vivo experiments, with COVID-19, 【제목키워드】 oral, development, Salmonella,